Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxycodone/Naloxone vs Codeine/Paracetamol in Chronic Low Back Pain or OA
NCT00784810Phase 4Completed
- Sponsor
- Napp Pharmaceuticals
- Start
- Feb 2009
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of oxycodone + naloxone in low back pain (LBP) and osteoarthritis (OA) (2 arms), sponsored by Napp Pharmaceuticals. Primary endpoint: Average Daily Pain Score Box Scale-11 (BS-11) at 12 weeks. Started Feb 2009; status: completed.
02
Drugs
oxycodone + naloxone
03
Conditions
low back pain (LBP)osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00784810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00784810.